Advertisement
 
YOU ARE HERE: LAT HomeCollectionsCephalon Inc
IN THE NEWS

Cephalon Inc

FEATURED ARTICLES
BUSINESS
September 8, 2004 | From Bloomberg News
Cephalon Inc., maker of the anti-drowsiness drug Provigil, said it received a subpoena from prosecutors in Philadelphia for documents relating to sales and marketing practices since 1998. Drug makers including AstraZeneca and Johnson & Johnson, Eli Lilly & Co. and Bristol-Myers Squibb Co. have received similar requests. West Chester, Pa.-based Cephalon's practices are proper and the company will cooperate, a spokesman said. Shares of the company fell $2 to $45.88 on Nasdaq.
ARTICLES BY DATE
BUSINESS
September 8, 2004 | From Bloomberg News
Cephalon Inc., maker of the anti-drowsiness drug Provigil, said it received a subpoena from prosecutors in Philadelphia for documents relating to sales and marketing practices since 1998. Drug makers including AstraZeneca and Johnson & Johnson, Eli Lilly & Co. and Bristol-Myers Squibb Co. have received similar requests. West Chester, Pa.-based Cephalon's practices are proper and the company will cooperate, a spokesman said. Shares of the company fell $2 to $45.88 on Nasdaq.
Advertisement
BUSINESS
December 29, 1998 | RICK WEISS, WASHINGTON POST
The Food and Drug Administration has approved a novel drug that keeps people with debilitating sleepiness awake and attentive yet has few of the side effects associated with caffeine, amphetamines and other commonly used stimulants. The drug, modafinil, was approved by the FDA for people with a serious sleep disorder called narcolepsy, which affects 1 out of 1,000 to 2,000 people and is characterized by sudden, overwhelming waves of intense sleepiness.
BUSINESS
December 29, 1998 | RICK WEISS, WASHINGTON POST
The Food and Drug Administration has approved a novel drug that keeps people with debilitating sleepiness awake and attentive yet has few of the side effects associated with caffeine, amphetamines and other commonly used stimulants. The drug, modafinil, was approved by the FDA for people with a serious sleep disorder called narcolepsy, which affects 1 out of 1,000 to 2,000 people and is characterized by sudden, overwhelming waves of intense sleepiness.
NEWS
June 8, 1996 | Associated Press
Patients with Lou Gehrig's disease should be allowed to take a free experimental drug that promises to slow, but not stop, their relentless paralysis, government advisors recommended Friday. If the Food and Drug Administration agrees, thousands of patients could begin vying to get Myotrophin free through a lottery while manufacturer Cephalon Inc. seeks full approval to sell it. The decision posed a dilemma for the FDA advisors.
BUSINESS
November 12, 1997
Federal-Mogul Corp., the Southfield, Mich.-based maker of automobile parts, plans to close 13 service centers by the end of the year, eliminating 25 to 30 jobs, in a move to cut costs and improve its distribution system. . . . ING Group of Amsterdam offered to buy Banque Bruxelles Lambert for $4.68 billion in cash, stock and warrants in a bid to expand its business in Belgium. ING already owns 20% of BBL. . . . Electronics company Kemet Corp. of Greenville, S.C.
BUSINESS
December 4, 2001 | Bloomberg News
Cephalon Inc., which makes neurological drugs, agreed to buy French drug maker Group Lafon for $450 million in cash. By gaining full control of Lafon's Provigil drug for narcolepsy, Cephalon expects to add about $80 million in sales and 3 cents a share to earnings in 2002. The West Chester, Pa.-based drug maker increased its 2002 earnings forecast to $1.03 a share. Sales will be $400 million to $410 million, Cephalon said.
BUSINESS
June 20, 2008 | From Times Wire Services
Government regulators said they were preparing to allow highly addictive medications to be prescribed online, a goal long sought by health insurers and large employers. Doctors are required by law to write out by hand prescriptions for controlled substances, which include attention deficit disorder drugs such as Shire Pharmaceuticals' Adderall and painkillers like Cephalon Inc.'s Fentora, which is for cancer patients. The concern is that patients are more likely to abuse these treatments, and their prescriptions should be monitored more closely.
BUSINESS
March 6, 2007 | From Bloomberg News
Rep. Henry A. Waxman (D-Los Angeles) opened an investigation of research and marketing related to medical devices and drugs made by Boston Scientific Corp., Johnson & Johnson, Eli Lilly & Co., AstraZeneca and Cephalon Inc. The companies received letters from Waxman, chairman of the House Oversight and Government Reform Committee, asking for documents including correspondence with the Food and Drug Administration.
BUSINESS
April 29, 1998 | Bloomberg News
Cephalon Inc. and Chiron Corp. are talking with the Food and Drug Administration as it nears a decision on whether they can market their Lou Gehrig's disease treatment, Myotrophin, in the U.S. "We are still in the throes of protracted discussions with the FDA on Myotrophin," said Edward Penhoet, chief executive and president of Emeryville-based Chiron. "We expect it will be decided one way or the other by May 12."
BUSINESS
July 11, 1995 | Compiled by Jack Searles
Amgen Inc., the Thousand Oaks biotechnology firm, says encouraging test results have been obtained for a drug it is co-developing with a New York firm to treat amyotrophic lateral sclerosis, or Lou Gehrig's disease. Results have been encouraging enough to begin a third-phase trial, said Amgen and its partner in the project, Regeneron Pharmaceuticals Inc. of Tarrytown, N.Y.
BUSINESS
April 2, 2002 | Bloomberg News
Cephalon Inc. ended a joint venture for marketing two of its drugs after analysts raised questions about accounting practices involving the partnership in the wake of Enron Corp.'s collapse. Cephalon shares rose $1.63 to $64.63 in Nasdaq trading. Cephalon, which makes neurological drugs, formed the joint venture with two outside investors in December 2001 to invest up to $50million to market its Provigil narcolepsy drug and Gabitril treatment for epileptic seizures, the company said. On Feb.
Los Angeles Times Articles
|